Pls find enclosed submission of Secretarial Compliance Report for the year ended 31.03.2026 pursuant to Reg 24A of LODR.
AJANTPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Ajanta Pharma Limited has submitted its Annual Secretarial Compliance Report for FY2026, verified by Practicing Company Secretaries D.G. Prajapati & Associates. The report confirms that the company has complied with all applicable SEBI regulations during the review period. One prior observation regarding delayed submission of Q4 FY2024 financial results to NSE (uploaded at 4:38 PM instead of within 30 minutes of board meeting conclusion) was addressed - the delay was due to technical issues with the NEAPS portal, and no penalty was levied. All 13 compliance checkpoints including secretarial standards, director disqualification, related party transactions, insider trading norms, and website disclosures show satisfactory compliance. No additional non-compliances were observed during the year.
This is a routine regulatory filing with no material concerns. The company has maintained clean SEBI compliance for FY2026, which is positive for investors. The historical observation about financial results submission delay has been adequately explained and carries no penalty, so it should not impact investor sentiment.